SCHEMBL17449178

SCHEMBL17449178

COc1ccc(C(C)=O)c(-c2ccccc2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
NNMT P40261 1/20 0.45
HCRTR1 O43613 2/20 0.43
HCRTR2 O43614 2/20 0.43
ALDH1A1 P00352 5/20 0.43
LMNA P02545 4/20 0.43
MTNR1A P48039 2/20 0.43
MTNR1B P49286 2/20 0.43
MAPT P10636 2/20 0.43
MAPK1 P28482 1/20 0.43
ATM Q13315 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
RAB9A P51151 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
NR4A2 P43354 2/20 0.40
KDM4E B2RXH2 1/20 0.40
PTGS1 P23219 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21056648 0.89 POLB (0.60) POLBTDP1NNMTHCRTR1HCRTR2
SCHEMBL17448834 0.83 POLB (0.46) POLBTDP1NNMTHCRTR1HCRTR2
SCHEMBL18197672 0.79 POLB (0.45) POLBTDP1NNMTHCRTR1HCRTR2
SCHEMBL12588561 0.77 GABRP (0.47) POLBALDH1A1LMNAMAPTMAPK1
SCHEMBL18136471 0.74 PDE10A (0.46) POLBTDP1ALDH1A1LMNAMAPT
SCHEMBL8443874 0.74 POLB (0.73) POLBTDP1NNMTALDH1A1MTNR1A
SCHEMBL31141991 0.74 POLB (0.73) POLBTDP1NNMTALDH1A1MTNR1A
SCHEMBL15308663 0.74 NNMT (0.71) POLBTDP1NNMTALDH1A1LMNA
SCHEMBL13853226 0.73 JUN (0.43) POLBALDH1A1LMNAMAPTMAPK1
SCHEMBL27248156 0.73 POLB (0.51) POLBTDP1NNMTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9745284-B2 2-pyridyloxy-4-ether orexin receptor antagonists MERCK SHARP & DOHME CORP. (US) 2017-08-29 US disclosed
US-20160102073-A1 2-HYDROXYMETHYL-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-04-14 US disclosed
US-20160016935-A1 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2016-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160016935-A1 2-PYRIDYLOXY-4-ETHER OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY2R POLB 4778/4885TDP1 4645/4885NNMT 2735/4885
US-20160102073-A1 2-HYDROXYMETHYL-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, CRHR2 POLB 4778/4885TDP1 4306/4885NNMT 1018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.